2-thia-5-azabicyclo[2.2.1]heptane 2,2-dioxide hydrochloride | 1481613-21-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻嗪类
• 英文名称: 2-thia-5-azabicyclo[2.2.1]heptane 2,2-dioxide hydrochloride
• 英文别名: 2λ6-thia-5-azabicyclo[2.2.1]heptane 2,2-dioxide;hydrochloride
• CAS: 1481613-21-1
• 化学式: C₅H₉NO₂S*ClH
• 分子量: 183.659
• InChiKey: CCLLUNMSIFQAIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.43
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  54.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,4-二氯-5-(碘甲基)嘧啶 、 2-thia-5-azabicyclo[2.2.1]heptane 2,2-dioxide hydrochloride 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 以44.69%的产率得到5-((2,4-dichloropyrimidin-5-yl)methyl)-2-thia-5-azabicyclo[2.2.1]heptane 2,2-dioxide
  参考文献：
  名称：

  DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY

  摘要：

  The invention provides diazepino-thieno-quinoxaline compounds, pharmaceutical compositions, their use for inhibiting MK2, and their use in the treatment of a disease or condition, such as an inflammatory disorder.

  公开号：

  WO2024044731A1

文献信息

• [EN] PYRAZOLE DERIVATIVES WHICH INHIBIT LEUKOTRIENE PRODUCTION<br/>[FR] DÉRIVÉS DE PYRAZOLE INHIBANT LA PRODUCTION DE LEUCOTRIÈNE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014014874A1

  公开（公告）日：2014-01-23

  The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A1, A2, L1 and B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其中A1、A2、L1和B如本文所定义。式（I）的化合物可用作白三烯A4水解酶（LTA4H）的抑制剂，并用于治疗与LTA4H相关的疾病。本发明还涉及包含式（I）的化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的方法。
• [EN] KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE KDM1A POUR LE TRAITEMENT D'UNE MALADIE
  申请人：[en]IMAGO BIOSCIENCES, INC.

  公开号：WO2023069884A1

  公开（公告）日：2023-04-27

  Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.